The concomitant use of N-BPs and statins, other mevalonate pathway inhibitors that block 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), has been proposed as an effective strategy for the treatment of malignant tumors due to the inhibition of FPP and GGPP biosynthesis from two points in the pathway [42]. The gene discussed is HMGCR; the disease is cancer.